Publications 2026

Molinaro A, Braadland PR, Carpino G, Carreras A, Nikolaidis M, Hanzely P, Beck KR, Ali AH, Bossen L, Frank A, Lundqvist A, Juran BD, Overi D, Geng L, Amundsen-Isaksen E, Reims HM, Björk I, Grzyb K, Abildgaard A, Folseraas T, Cornillet M, Helgadóttir H, McCauley BM, Cristoferi L, Carbone M, Cardinale V, Høivik ML, Engesæter LK, Tjønnfjord SKV, McCann A et al. (2026)
Gut microbiota-derived imidazole propionate promotes primary sclerosing cholangitis via p38 signalling
Nat Metab (in press)
DOI 10.1038/s42255-026-01600-1, PubMed 42698000

Valestrand L, Nordhus KS, Claudel T, Øgaard J, Frank A, Amundsen-Isaksen E, Fuchs C, Berntsen NL, Chung BK, Jiang X, Trauner M, Melum E (2026)
Natural Killer T cells promote cholestatic liver disease independent of antigen presentation by cholangiocytes
Hepatol Commun, 10 (2)
DOI 10.1097/HC9.0000000000000862, PubMed 41543487

Publications 2022

Brinch SA, Amundsen-Isaksen E, Espada S, Hammarström C, Aizenshtadt A, Olsen PA, Holmen L, Høyem M, Scholz H, Grødeland G, Sowa ST, Galera-Prat A, Lehtiö L, Meerts IATM, Leenders RGG, Wegert A, Krauss S, Waaler J (2022)
The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models
Cancer Res Commun, 2 (4), 233-245
DOI 10.1158/2767-9764.CRC-22-0027, PubMed 36873622

Publications 2021

Leenders RGG, Brinch SA, Sowa ST, Amundsen-Isaksen E, Galera-Prat A, Murthy S, Aertssen S, Smits JN, Nieczypor P, Damen E, Wegert A, Nazaré M, Lehtiö L, Waaler J, Krauss S (2021)
Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II
J Med Chem, 64 (24), 17936-17949
DOI 10.1021/acs.jmedchem.1c01264, PubMed 34878777